Eisai and Biogen presented data at the Alzheimer’s Association International Conference 2026 in London showing that a lecanemab subcutaneous autoinjector (LEQEMBI) produced exposure, efficacy and safety comparable to the approved intravenous initiation regimen in people with early Alzheimer’s disease. According…
Browsing: All news
Category Added in a WPeMatico Campaign
Cognito Therapeutics presented exploratory cerebr
At the Alzheimer’s Association International Co
NeuroTherapia will present data from its recently
Indiana University and PharmatrophiX presented a
Aeon welcomed the establishment of the Dubai Long
Eisai presented data at the Alzheimer’s Associa
The New England Journal of Medicine published a p
New study shows long-assumed irreversible AGEs c
Positive Phase 3 results hint that the next obes